About 30 to 83.7 million adults in the United States have Obstructive Sleep Apnea (OSA), notes American Lung Association. Roughly 80 per cent of these cases remain undiagnosed. However, now, a simple daily pill, an old drug, could just be the solution. Scientists in Sweden and other places too, have been studying the anti-seizure medicine sultiame as a treatment for OSA. In their latest Phase II trial, the scientists found that people on sultiame experienced an improvement in their apsea symptoms, and their sleep quality too improved as compared to those taking placebo. The results points towards the potential of sultiame becoming an effective option for people with sleep apnea, especially those who cannot tolerate continuous positive airway pressure (CPACP) machines. The findings are published in The Lancet, and the researchers noted: "These findings offer perspective for a pharmaceutical approach to treatment of patients with obstructive sleep apnea."Sleep Apnea Pill: What Is This Condition?OSA is the most common form of sleep apnea, and it happens when airway muscles physically block a person's breathing during sleep. This could pause the body to wake up enough to start breathing again, only for the cycle to restart throughout the night, anywhere from five to 100 times an hour. This also causes low oxygen levels and disturb people's sleep and, over time, can raise the risk of other long-term health problems, which could include heart diseases and even dementia. What CPAP machines do is they use air pressure to keep the airways open during sleep. While machines are an effective way, some people have trouble using them long term, which is why some companies use less cumbersome interventions, including medicines.Read: Harish Rana Case Highlights Why Planning For A Living Will Is Important Sleep Apnea Pill: What Was It Used For?Sultimae or sulthiame was first launched in the 1960s by Bayger AG as an anticonvulsant - which means, it was a drug designed to treat epilepsy and prevent seizures by stabilizing nerve cell membranes and reducing abnormal, excessive electrical activity in the brain. What the drug does is, it inhibits carbonic anhydrase, an enzyme that plays a role in regulating our breathing. Research also suggested that this could help people with sleep apnea by preventing airway collapse. The US-based Apnimed, in collaboration with the Japenese company Shionogi & Co., Ltd., have been looking to develop sultiame as a sleep apnea treatment. How Well Has The Sleep Apnea Pill Been Tested?The phase II of the trial involved 298 patients. Of them were untreated, moderate and people with severe sleep apnea. The people were observed for over a 15-week period, of them, half were randomized to a placebo pill to be taken right before bed, while rest were given varying doses of sultiame. The results showed that people who took sultiame saw a noticeable decrease in apnea symptoms and also witnessed improvements in their sleep quality and daytime sleepiness. People in the highest dose group saw the most improvement, with apnea symptoms being reduced up to 47 per cent. “It feels like a breakthrough, and we now look forward to larger and longer studies to determine whether the effect is sustained over time and whether the treatment is safe for broader patient groups,” said study researcher Jan Hedner, a senior professor of pulmonary medicine at the University of Gothenburg.